Browsing Tag
exidavnemab
1 post
BioArctic advances exidavnemab phase 2a cohorts after safety review
BioArctic expands its Phase 2a trial for exidavnemab after a successful safety review. Read how this impacts Parkinson’s and MSA drug development today.